ascorbic-acid has been researched along with dihydroxyfumarate* in 5 studies
5 other study(ies) available for ascorbic-acid and dihydroxyfumarate
Article | Year |
---|---|
Potentiometric assessment of iron release during ferritin reduction by exogenous agents.
This work studied the possibilities for quantitative determination of iron mobilization in connection with ferritin reduction by ascorbic acid (vitamin C) and sodium dithionite in vitro. The iron storage protein was incubated with an excess of reductant in aerobic conditions in the absence of complexing agents in the medium. The release of Fe(2+) was let to go to completion, and the overall content of Fe(2+) in the solution was evaluated with the aid of potentiometric titration using Ce(4+) as an oxidizing titrant. Results suggest a moderate iron efflux under the influence of the chosen reducing agents. Although such a reduction of the protein mineral core by dihydroxyfumarate contributes greatly to the iron mobilization, ferritin behavior with vitamin C and dithionite seems to be different. Although redox properties of dihydroxyfumarate are determined by hydroxyl groups similar to those of ascorbic acid, the two compounds differ significantly in structure, and this could be the basis for an explanation of the specificities in their interaction with ferritin. As revealed by the study, potentiometric titration promises to be a reliable tool for evaluation of the amount of Fe(2+) present in the solution as a result of the reduction of the ferritin's mineral core. Topics: Ascorbic Acid; Cerium; Dithionite; Ferritins; Fumarates; Iron; Oxidation-Reduction; Potentiometry | 2010 |
SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant.
The antioxidant effects of SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, were studied and compared with carvedilol and other antioxidants such as U78517F, U74500A and probucol. SB 211475 inhibited Fe(2+)-vitamin C-initiated lipid peroxidation, assessed as thiobarbituric acid reactive substance, in brain-homogenate with an IC50 of 0.28 microM. Under the same conditions, the IC50s of probucol, carvedilol, U74500A and U78517F were 50, 8.1, 0.71 and 0.16 microM, respectively. SB 211475 inhibited oxidation of human low density lipoprotein by mouse macrophages with an IC50 of 0.043 microM. In the same model, the IC50s of carvedilol, U78517F and probucol were 3.8, 0.15, and 0.80 microM, respectively. SB 211475 protected cultured bovine pulmonary artery endothelial cells against hydroxyl radical-initiated lipid peroxidation (IC50 = 0.15 microM) and cell damage (lactate dehydrogenase release, IC50 = 0.16 microM), and promoted cell survival with an EC50 of 0.13 microM. SB 211475 also protected endothelial cells against xanthine/xanthine oxidase-initiated cytotoxicity and protected rat cerebellar neurons from hydroxyl radical-mediated cell death (EC50 = 0.19 microM). Moreover, SB 211475 inhibited superoxide (O2-) release from human neutrophils stimulated by phorbol myristate acetate. These observations indicate that SB 211475 is a potent antioxidant and may potentially contribute to the therapeutic effects of carvedilol in vivo. Topics: Adenosine Diphosphate; Animals; Antihypertensive Agents; Antioxidants; Ascorbic Acid; Brain; Carbazoles; Cattle; Cell Death; Cells, Cultured; Chromans; Endothelium, Vascular; Fumarates; Humans; Iron; Lipid Peroxidation; Lipoproteins, LDL; Macrophages; Male; Mice; Neurons; Neutrophils; Nicardipine; Oxidation-Reduction; Piperazines; Propanolamines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Superoxides; Tetradecanoylphorbol Acetate; Xanthine; Xanthine Oxidase; Xanthines | 1994 |
Reaction of compound III of myeloperoxidase with ascorbic acid.
A relatively pure and stable compound III of bovine spleen myeloperoxidase was prepared from native enzyme using the aerobic oxidation of dihydroxyfumarate to generate O2-(.). Spectral scans show well defined peaks at 450 and 625 nm and an isosbestic point between compound III and native enzyme at 440 nm. Compound III decayed to native enzyme without any detectable intermediate. The rate of decay was faster at alkaline pH values and also in the presence of superoxide dismutase. Ascorbic acid reduces compound III to native enzyme with a second order rate constant of (4.0 +/- 0.1) x 10(2) M-1 s-1. The ascorbic acid reduction of compound III has potential physiological relevance since it could help maintain the catalytic cycle of myeloperoxidase to generate the bactericidal agent hypochlorous acid. Topics: Animals; Ascorbic Acid; Cattle; Enzyme Stability; Fumarates; Hydrogen-Ion Concentration; Kinetics; Peroxidase; Spectrophotometry; Spleen; Superoxide Dismutase | 1990 |
Reductive release of ferritin iron: a kinetic assay.
Ferritin iron release, a process of considerable interest in biology and medicine, occurs most readily in the presence of reducing agents. Here is described a kinetic assay for measuring the rate of ferritin iron removal promoted by various reductants. The new procedure uses ferrozine as a chromophoric, high-affinity chelator for the product, Fe(II). The initial rate of iron release is quantified by continuous spectrophotometric measurement of the Fe(ferrozine)2/3+ complex which absorbs maximally at 562 nm. The initial rate of iron mobilization is dependent on reductant concentration, but not on the concentration of the chelating agent, ferrozine. Saturation kinetics are observed for all reductants, including dihydroxyfumarate, cysteine, caffeic acid, ascorbate, and glutathione. Superoxide dismutase greatly inhibits ferritin iron release by ascorbate, but has little or no effect on the reducing action of dihydroxyfumarate, cysteine, caffeic acid, or glutathione. Ferritin iron removal by dihydroxyfumarate was inhibited by various metal ions. This new assay may be used for rapid screening of test compounds for treatment of iron overload and for investigation of the mechanistic aspects of ferritin iron reduction. Topics: Animals; Ascorbic Acid; Ferritins; Ferrozine; Fumarates; In Vitro Techniques; Iron; Kinetics; Oxidation-Reduction | 1988 |
Hydroxylation by hemoglobin-containing systems: activities and regioselectivities.
Topics: Aniline Compounds; Ascorbic Acid; Cytochrome P-450 Enzyme System; Fumarates; Hemoglobins; Humans; Hydroxylation; Kinetics; Methemoglobin; NAD; Oxyhemoglobins; Riboflavin | 1984 |